1. Field of the Invention
The present invention relates to medical devices, and more particularly, to airway products, such as tracheal tubes and cuffs.
2. Description of the Related Art
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
In the course of treating a patient, a tube or other medical device may be used to control the flow of air, food, fluids, or other substances into and/or out of the patient. For example, medical devices such as tracheal tubes may be used to control the flow of one or more substances into or out of a patient. In many instances it is desirable to provide a seal between the outside of the tube or device and the interior of the passage in which the tube or device is inserted. In this way, substances can only flow through the passage via the tube or other medical device, allowing a medical practitioner to maintain control over the type and amount of substances flowing into and out of the patient.
For example, tracheal tubes may be used to control the flow of air or other gases through a patient's trachea. Such tracheal tubes may include endotracheal (ET) tubes or tracheostomy tubes. To seal these types of tracheal tubes, an inflatable cuff may be associated with these tubes. When inflated, the cuff generally expands into the surrounding trachea to seal the tracheal passage around the tube.
However, to fit a range of trachea anatomies and to provide low intra cuff pressure, cuff diameters are typically about one and a half times the diameter of the average trachea. Therefore, when inserted in an average-sized trachea, such a cuff is unable to fully expand and will fold in on itself within the trachea. These folds may serve as leak paths that allow mucosal secretions to flow past the cuff and enter the lung. Because mucosal secretions may harbor microbes, it is desirable to prevent such secretions from entering the lungs.
Certain types of cuffs are manufactured from materials that have a lower tendency to form leak paths. For example, high pressure cuffs are typically made of highly elastic materials that may form a relatively smooth seal against the trachea. However, such cuffs have associated disadvantages. Due to their elastic properties, high pressure cuffs are often inflated to at least twice the intracuff pressure of lower pressure cuffs in order to form a sufficient tracheal seal. Such high pressures may cause patient discomfort. Further, the mechanical pressure of the high pressure cuff against the tracheal walls may also cause temporary damage to cilial structures in the trachea that are associated with airway particle clearance.
Other types of cuffs may include swellable layers that may be involved in providing a physical barrier to fill the leak paths. However, such physical barriers may be nonetheless permeable to microbial infiltration. For example, such cuffs may employ a hydrogel that may swell into the folds of the cuff. However, many hydrogel coatings may be too porous to prevent the microbes in mucosal secretions from flowing through leak paths in the cuff. Further, many hydrogel coatings are dynamic in nature, with constantly changing pore sizes.
Certain aspects commensurate in scope with the originally claimed invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be set forth below.
There is provided a medical device that includes an inflatable balloon cuff; and a filtration layer having a pore size of less than 5 microns disposed on a tissue-contacting surface of the balloon cuff.
There is also provided a method of manufacturing a medical device that includes providing an inflatable balloon cuff; and providing a filtration layer having a pore size of less than 5 microns disposed on a tissue-contacting surface of the balloon cuff.
There is also provided a method of sealing a patient's trachea that includes inserting an inflatable balloon cuff into a patient's trachea; applying a monomer solution to a surface of the balloon cuff; and cross-linking the monomer solution to produce a filtration layer having a pore size of less than 5 microns.
There is also provided a medical device that includes: an inflatable balloon cuff; and a filtration layer disposed on a tissue-contacting surface of the balloon cuff, wherein the filtration layer is adapted to filter out microbes from mucosal secretions.
There is also provided a method that includes: filtering out microbes from mucosal secretions before they enter the folds of an inflatable balloon cuff.
Advantages of the invention may become apparent upon reading the following detailed description and upon reference to the drawings in which:
One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
In accordance with some aspects of the present technique, an inflatable cuff is provided that includes a filtration layer that is adapted to filter mucosal secretions before the secretions travel down any folds in the cuff and into the lungs. The filtration layer may be characterized as having a limited pore size that is able to filter out microbes. It is desirable to provide a medical balloon, such as an endotracheal cuff or other medical device, which may substantially seal the passage in which the cuff is inserted so that mechanical ventilation can be used to introduce air, oxygen, or medications into the lungs. As cuffs are typically sized to be larger than the trachea when fully inflated in order to effectively seal a wide range of patient tracheas, the cuff walls are unable to inflate to their maximum diameter and may fold in on themselves, which may cause wrinkles and leak paths to form. These leak paths may be conduits for microbes, for example those found in mucosal secretions, to travel into to lungs. The cuffs including filtration layers, as provided herein, may filter out microbes from the mucosal secretions that enter cuff leak paths to travel into the lungs.
A filtration layer may be any suitable material having a pore size smaller than the microbes that are being filtered. As most bacteria have diameters that are microns in scale, a suitable pore size may be on the lower end of the micron scale in order to filter out most bacteria. Many microbes fall into the size range of 0.2-20 microns. In certain embodiments, microbes fall into the size range of 3-5 microns. Exemplary microbes to be filtered include Puedomonas aeruginosa, Staphylococcus aureus, Enterobacter spp, Haemophilus influenza, Streptococcus spp, Candida ablicans (yeast), Stenotrophomonas multiphilia, Methicillin Resistant Staphyloccus aureus, and others, including viruses. In certain embodiments, an appropriate pore size for the filtration layer is less than 5 microns or less than 2 microns. In other embodiments, the pore size may be less than 0.2 microns in order to filter out the broadest range of microbes. Further, as certain microbes may be capable of changing morphology under pressure in order to “squeeze” through pores having a slightly smaller diameter, a pore size of less than 0.2 microns may be advantageous as such a size may generally be substantially smaller than most bacteria. Pore size may be defined as the average diameter, or a range of diameters, of the individual pores in a membrane. Generally, pore size may be determined statistically by the average dimension of the smallest particle that will pass through the material. Several standardized tests are available to determine pore size. For example, the bubble point test is evaluates performance under aqueous conditions. Pore size may also be calculated from measurements of capillary force, pressure, and water height. One such method is described in ASTM F 316.
The medical cuffs as provided herein may be used in conjunction with any suitable medical device. In certain embodiments, the cuffs as provided herein may be used in conjunction with a catheter, a stent, a feeding tube, an intravenous tube, an endotracheal tube, a tracheostomy tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments.
An example of a cuff used in conjunction with a medical device is a cuffed endotracheal tube 10, depicted in
The cuff 12 may be formed from materials having suitable mechanical properties (such as puncture resistance, pin hole resistance, tensile strength), chemical properties (such as forming a suitable bond to the tube 16), and biocompatibility. In one embodiment, the walls of the inflatable cuff 12 are made of a polyurethane having suitable mechanical and chemical properties. An example of a suitable polyurethane is Dow Pellethane® 2363-80A. In another embodiment, the walls of the inflatable cuff 12 are made of a suitable polyvinyl chloride (PVC). Other suitable materials include polypropylene, polyethylene teraphthalate (PETP), low-density polyethylene (LDPE), silicone, neoprene, or polyisoprene.
The filtration layer 14 is configured to be disposed on the outer, tissue-contacting surface of the cuff 12. The filtration layer 14 reduces or prevents the passage of microbes larger than a certain size.
Further, the filtration layer 14 may be disposed on the cuff 12 such that as the cuff 12 folds in on itself to form wrinkles 25, the filtration layer 14 creates a vertical channel down the wrinkle 25. In such an embodiment, the filtration layer 14 may be a few microns to several millimeters in thickness in order to fill the fold of the cuff, depending on how the cuff 12 folds. In certain embodiments, it may be advantageous to use a filtration layer 14 that may have a surface treatment or charge, such that the folds of the cuff 12 will be attracted to one another to encourage formation of the vertical channel. For example, a polymer filtration layer 14 may be formed from cross-linked amphipathic polymers such as having hydrophilic branches and a hydrophobic backbone that may adhere easily to a hydrophobic cuff 12. In alternative embodiments, the filtration layer 14 may undergo a surface treatment, such as plasma treatment, in order to modify its surface characteristics. Further, a hydrophilic filtration layer 14 may also encourage formation of a seal of the cuff walls against the mucosal tissue, which is generally hydrophilic in nature.
In other embodiments, the filtration layer 14 may be disposed on only a portion of the cuff 12. The filtration layer 14 may be disposed on the cuff such that it creates a barrier to microbial entry into any wrinkles 25. Shown in
The filtration layer 14 may be any suitable material with an appropriate pore size. For example, the filtration layer 14 may be a microporous polymer or polymer mixture. The pore size of the polymer mixture may be adjusted by increased cross-linking of the polymer. For example, the filtration layer 14 may include a microporous polypropylene blend. Such a microporous polymer may be fabricated by compounding a polypropylene major phase system of less than 15% total weight with a polystyrene minor phase as detailed in “Preparation of Microporous Films from Immiscible Blends via Melt Processing,” Chandavasu, et al. Journal of Plastic Film and Sheeting, Vol. 16, No. 4, 288-300 (2000). Alternatively, the filtration layer 14 may be a polyacrylamide polymer network. The acrylamide polymerization solution may be a 4-5% solution (acrylamide/bisacrylamide 19/1) in water/glycerol, with a nominal amount of initiator added. The solution may be polymerized and cross-linked either by ultraviolet radiation or by thermal initiation at elevated temperature. The pore size of the gel may be controlled by changing the amount of crosslinker and the percent of solids in the monomer solution. The cuff 12 may be dipped into the polyacrylamide solution, and removed before initiation of cross-linking. The solution characteristics and dip times may be adjusted, depending on the desired thickness of the filtration layer 14. Polyethyleneimine, polyacrylamide, polymers of dimethylaminoethylmethacrylate, polymers of ammonio methacrylate, and copolymers of dimethylaminoethylmethacrylate and ammonio methacrylate. Alternatively, the filtration layer 14 may be an interpenetrating polymer network, such as a hydrogel network. The pore size of such networks may be controlled through the amount of cross-linking as well as through the monomer or oligomer size.
The filtration layer 14 may also be a homogeneous hydrogel. Such a hydrogel may be polymerized to have the appropriate microporosity through bulk polymerization, i.e. polymerization in the absence of added solvent. Bulk polymerization of a homogeneous hydrogel initially produces a glassy, transparent polymer matrix that is relatively hard. When immersed in water, the glassy matrix swells to become soft and flexible. Although it permits the transfer of water and some low-molecular-weight solutes, such a swollen polymer matrix hydrogel is considered non-porous. The pores between polymer chains are in fact the only spaces available for the mass transfer, and the pore size is within the range of molecular dimensions (a few nanometers or less). Suitable hydrogel monomers may include polyethylene glycol and methacrylic acid.
The distance between crosslinks, or crosslink density, is a critical factor in determining the pore size of a hydrogel “filter”. The crosslink density can be controlled by factors such as the crosslinking agent concentration, the molecular weight of the crosslinker, and the state of the hydrogel during the crosslinking process. For instance, the amount the hydrogel is swollen during the crosslinking process will have a large impact on the potential swelling of the final hydrogel. This is due to the distance between the polymer chains under different solvent conditions during the crosslinking process. Because of the high percentage of swelling that occurs in hydrogels, it is possible for hydrogels pressed together to intermingle and achieve molecular entanglement. This helps provide a filtering mechanism in the folds that form along the cuff 12 after inflation within the trachea. In this way, a contiguous microbe filter can be achieved.
In another specific embodiment, the filtration layer 14 may be a layer formed from small peptides with the characteristics of self-assembling into a film, such as those detailed in U.S. Pat. No. 7,098,028. For example, the peptide EAK16 (AEAEAKAKAEAEAKAK) self-assembles into stable macroscopic membranes in the presence of millimolar concentrations of salt. Peptides having these properties participate in intermolecular interactions which result in the formation and stabilization of beta-sheets at the secondary structure level and interwoven filaments at the tertiary structure level.
A variety of manufacturing techniques can be used to apply the filtration layer 14 to the cuff 12. For example, the cuff 12 can be dipped into a solution containing monomers that may be polymerized on the cuff 12. In other embodiments, the filtration layer 14 may be co-extruded with the cuff 12 or may be molded, co-extrusion blow-molded, electrostatically applied, extruded and applied to a balloon blowing apparatus, or sprayed.
The tracheal cuffs of the present techniques may be incorporated into systems that facilitate positive pressure ventilation of a patient, such as a ventilator. Such systems may typically include connective tubing, a gas source, a monitor, and/or a controller. The controller may be a digital controller, a computer, an electromechanical programmable controller, or any other control system.
Typically, endotracheal cuffs are inflated within a patient's trachea such that the intra cuff pressure is approximately 20-25 cm H2O. Endotracheal cuffs utilizing inflation pressures significantly greater 50 cm H2O may be referred to as high-pressure cuffs, while cuffs that are able to effectively seal the trachea at pressures less than 30 cm H2O may be considered low-pressure cuffs. In certain embodiments, intra cuff inflation pressures of 10-30 cm H2O may be used with the cuffs of the present techniques.
While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.
Number | Name | Date | Kind |
---|---|---|---|
2927584 | Wallace | Mar 1960 | A |
3769983 | Merav | Nov 1973 | A |
3810474 | Cross | May 1974 | A |
3822238 | Blair et al. | Jul 1974 | A |
3913565 | Kawahara | Oct 1975 | A |
3971385 | Corbett | Jul 1976 | A |
3975350 | Hudgin et al. | Aug 1976 | A |
3995643 | Merav | Dec 1976 | A |
4022217 | Rowean | May 1977 | A |
4106509 | McWhorter | Aug 1978 | A |
4130617 | Wallace | Dec 1978 | A |
4230108 | Young | Oct 1980 | A |
4231365 | Scarberry | Nov 1980 | A |
4235239 | Elam | Nov 1980 | A |
4340046 | Cox | Jul 1982 | A |
4569344 | Palmer | Feb 1986 | A |
4638539 | Palmer | Jan 1987 | A |
4649913 | Watson | Mar 1987 | A |
4696296 | Palmer | Sep 1987 | A |
4700700 | Eliachar | Oct 1987 | A |
4791920 | Fauza | Dec 1988 | A |
4825859 | Lambert | May 1989 | A |
4825861 | Koss | May 1989 | A |
4834726 | Lambert | May 1989 | A |
4836199 | Palmer | Jun 1989 | A |
4838255 | Lambert | Jun 1989 | A |
4850348 | Pell et al. | Jul 1989 | A |
4867153 | Lorenzen et al. | Sep 1989 | A |
4872579 | Palmer | Oct 1989 | A |
4886059 | Weber | Dec 1989 | A |
4927412 | Menasche | May 1990 | A |
4938741 | Lambert | Jul 1990 | A |
4963313 | Noddin et al. | Oct 1990 | A |
4967743 | Lambert | Nov 1990 | A |
4979505 | Cox | Dec 1990 | A |
5020534 | Pell et al. | Jun 1991 | A |
5021045 | Buckberg et al. | Jun 1991 | A |
5025806 | Palmer et al. | Jun 1991 | A |
5029580 | Radford et al. | Jul 1991 | A |
5033466 | Weymuller, Jr. | Jul 1991 | A |
5060646 | Page | Oct 1991 | A |
5065754 | Jensen | Nov 1991 | A |
5074840 | Yoon | Dec 1991 | A |
5076268 | Weber | Dec 1991 | A |
5098379 | Conway et al. | Mar 1992 | A |
5103816 | Kirschbaum et al. | Apr 1992 | A |
5107829 | Lambert | Apr 1992 | A |
5120322 | Davis et al. | Jun 1992 | A |
5122122 | Allgood | Jun 1992 | A |
5133345 | Lambert | Jul 1992 | A |
5135516 | Sahatjian et al. | Aug 1992 | A |
5137671 | Conway et al. | Aug 1992 | A |
5158569 | Strickland et al. | Oct 1992 | A |
5165420 | Strickland | Nov 1992 | A |
5176638 | Don Michael | Jan 1993 | A |
5190810 | Kirschbaum et al. | Mar 1993 | A |
5199427 | Strickland | Apr 1993 | A |
5201310 | Turnbull et al. | Apr 1993 | A |
5207643 | Davis | May 1993 | A |
5213576 | Abiuso et al. | May 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5218957 | Strickland | Jun 1993 | A |
5230332 | Strickland | Jul 1993 | A |
5233979 | Strickland | Aug 1993 | A |
5246012 | Strickland | Sep 1993 | A |
5250070 | Parodi | Oct 1993 | A |
5251619 | Lee | Oct 1993 | A |
5261896 | Conway et al. | Nov 1993 | A |
5263478 | Davis | Nov 1993 | A |
5269770 | Conway et al. | Dec 1993 | A |
5277177 | Page et al. | Jan 1994 | A |
5290585 | Elton | Mar 1994 | A |
5304121 | Sahatjian | Apr 1994 | A |
5331027 | Whitbourne | Jul 1994 | A |
5360402 | Conway et al. | Nov 1994 | A |
5370656 | Shevel | Dec 1994 | A |
5370899 | Conway et al. | Dec 1994 | A |
5374261 | Yoon | Dec 1994 | A |
5392787 | Yoon | Feb 1995 | A |
5397302 | Weaver et al. | Mar 1995 | A |
5407423 | Yoon | Apr 1995 | A |
5417671 | Jackson | May 1995 | A |
5423745 | Todd et al. | Jun 1995 | A |
5439457 | Yoon | Aug 1995 | A |
5443063 | Greenberg | Aug 1995 | A |
5447505 | Valentine et al. | Sep 1995 | A |
5451204 | Yoon | Sep 1995 | A |
5466231 | Cercone et al. | Nov 1995 | A |
5469864 | Rosenblatt | Nov 1995 | A |
5482740 | Conway et al. | Jan 1996 | A |
5484426 | Yoon | Jan 1996 | A |
5487730 | Marcadis et al. | Jan 1996 | A |
5494029 | Lane et al. | Feb 1996 | A |
5501669 | Conway et al. | Mar 1996 | A |
5507284 | Daneshvar | Apr 1996 | A |
5509899 | Fan et al. | Apr 1996 | A |
5524642 | Rosenblatt | Jun 1996 | A |
5545132 | Fagan et al. | Aug 1996 | A |
5556391 | Cercone et al. | Sep 1996 | A |
5593718 | Conway et al. | Jan 1997 | A |
5599292 | Yoon | Feb 1997 | A |
5599299 | Weaver et al. | Feb 1997 | A |
5599321 | Conway et al. | Feb 1997 | A |
5611336 | Page et al. | Mar 1997 | A |
5613950 | Yoon | Mar 1997 | A |
5649902 | Yoon | Jul 1997 | A |
5653229 | Greenberg | Aug 1997 | A |
5670111 | Conway et al. | Sep 1997 | A |
5674192 | Sahatjian et al. | Oct 1997 | A |
5693014 | Abele et al. | Dec 1997 | A |
5694922 | Palmer | Dec 1997 | A |
5697365 | Pell | Dec 1997 | A |
5700239 | Yoon | Dec 1997 | A |
5715815 | Lorenzen et al. | Feb 1998 | A |
5720726 | Marcadis et al. | Feb 1998 | A |
5722931 | Heaven | Mar 1998 | A |
5730123 | Lorenzen | Mar 1998 | A |
5733252 | Yoon | Mar 1998 | A |
5735271 | Lorenzen et al. | Apr 1998 | A |
5765559 | Kim | Jun 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5810786 | Jackson et al. | Sep 1998 | A |
5819723 | Joseph | Oct 1998 | A |
5819733 | Bertram | Oct 1998 | A |
5827215 | Yoon | Oct 1998 | A |
5843017 | Yoon | Dec 1998 | A |
5843028 | Weaver et al. | Dec 1998 | A |
5843060 | Cercone | Dec 1998 | A |
5843089 | Sahatjian et al. | Dec 1998 | A |
5868719 | Tsukernik | Feb 1999 | A |
5908406 | Ostapchenko | Jun 1999 | A |
5951597 | Westlund et al. | Sep 1999 | A |
5954706 | Sahatjian | Sep 1999 | A |
5954740 | Ravenscroft et al. | Sep 1999 | A |
5971954 | Conway et al. | Oct 1999 | A |
5976072 | Greenberg | Nov 1999 | A |
5997503 | Willis et al. | Dec 1999 | A |
5997546 | Foster et al. | Dec 1999 | A |
6010480 | Abele et al. | Jan 2000 | A |
6012451 | Palmer | Jan 2000 | A |
6048332 | Duffy et al. | Apr 2000 | A |
6110192 | Ravenscroft et al. | Aug 2000 | A |
6120904 | Hostettler et al. | Sep 2000 | A |
6129547 | Cise | Oct 2000 | A |
6152136 | Pagan | Nov 2000 | A |
6169123 | Cercone | Jan 2001 | B1 |
6210364 | Anderson et al. | Apr 2001 | B1 |
6214895 | Cercone | Apr 2001 | B1 |
6227200 | Crump et al. | May 2001 | B1 |
6240321 | Janke et al. | May 2001 | B1 |
6248088 | Yoon | Jun 2001 | B1 |
6264631 | Willis et al. | Jul 2001 | B1 |
6264633 | Knorig | Jul 2001 | B1 |
6277089 | Yoon | Aug 2001 | B1 |
6312421 | Boock | Nov 2001 | B1 |
6322586 | Monroe et al. | Nov 2001 | B1 |
6364856 | Ding et al. | Apr 2002 | B1 |
6378521 | Van Den Berg | Apr 2002 | B1 |
6394093 | Lethi | May 2002 | B1 |
6395012 | Yoon et al. | May 2002 | B1 |
6398266 | Crump | Jun 2002 | B1 |
6409716 | Sahatjian et al. | Jun 2002 | B1 |
6481436 | Neame | Nov 2002 | B1 |
6494203 | Palmer | Dec 2002 | B1 |
6524274 | Rosenthal et al. | Feb 2003 | B1 |
6526977 | Göbel | Mar 2003 | B1 |
6537194 | Winkler | Mar 2003 | B1 |
6543451 | Crump et al. | Apr 2003 | B1 |
6551272 | Gobel | Apr 2003 | B2 |
6572813 | Zhang et al. | Jun 2003 | B1 |
6584970 | Crump et al. | Jul 2003 | B1 |
6588425 | Rouns et al. | Jul 2003 | B2 |
6588427 | Carlsen et al. | Jul 2003 | B1 |
6602218 | Yoon | Aug 2003 | B2 |
6602219 | Madsen et al. | Aug 2003 | B2 |
6609520 | Carlsen et al. | Aug 2003 | B1 |
6612304 | Cise et al. | Sep 2003 | B1 |
6612305 | Fauza | Sep 2003 | B2 |
6613025 | Palasis | Sep 2003 | B1 |
6615835 | Cise et al. | Sep 2003 | B1 |
6620128 | Simhambhatla | Sep 2003 | B1 |
6623450 | Dutta | Sep 2003 | B1 |
6629530 | Cise | Oct 2003 | B2 |
6632091 | Cise et al. | Oct 2003 | B1 |
6651664 | Lomholt | Nov 2003 | B1 |
6688306 | Cise et al. | Feb 2004 | B1 |
6698424 | Madsen et al. | Mar 2004 | B2 |
6705320 | Anderson | Mar 2004 | B1 |
6722368 | Shaikh | Apr 2004 | B1 |
6726696 | Houser et al. | Apr 2004 | B1 |
6745773 | Gobel | Jun 2004 | B1 |
6767340 | Willis et al. | Jul 2004 | B2 |
6769430 | Carlsen et al. | Aug 2004 | B1 |
6770066 | Weaver et al. | Aug 2004 | B1 |
6786876 | Cox | Sep 2004 | B2 |
6790221 | Monroe et al. | Sep 2004 | B2 |
6796309 | Nash et al. | Sep 2004 | B2 |
6802317 | Göbel | Oct 2004 | B2 |
6805125 | Crump et al. | Oct 2004 | B1 |
6808521 | McMichael | Oct 2004 | B1 |
6814730 | Li | Nov 2004 | B2 |
6890339 | Sahatjian et al. | May 2005 | B2 |
6908449 | Willis et al. | Jun 2005 | B2 |
6916307 | Willis et al. | Jul 2005 | B2 |
6923786 | Rouns et al. | Aug 2005 | B2 |
6997909 | Goldberg | Feb 2006 | B2 |
7040321 | Gobel | May 2006 | B2 |
7040322 | Fortuna | May 2006 | B2 |
7066905 | Squire et al. | Jun 2006 | B2 |
7098028 | Holmes et al. | Aug 2006 | B2 |
7147252 | Teuscher et al. | Dec 2006 | B2 |
7258120 | Melker | Aug 2007 | B2 |
20020032407 | Willis et al. | Mar 2002 | A1 |
20020082552 | Ding et al. | Jun 2002 | A1 |
20020195110 | Watton | Dec 2002 | A1 |
20030073625 | Redman et al. | Apr 2003 | A1 |
20030116162 | Madsen et al. | Jun 2003 | A1 |
20030225369 | McMichael et al. | Dec 2003 | A1 |
20030225392 | McMichael et al. | Dec 2003 | A1 |
20030225393 | McMichael et al. | Dec 2003 | A1 |
20040079376 | Melker | Apr 2004 | A1 |
20040106899 | McMichael et al. | Jun 2004 | A1 |
20040106900 | Triebes et al. | Jun 2004 | A1 |
20040106901 | Letson et al. | Jun 2004 | A1 |
20040116898 | Hawk | Jun 2004 | A1 |
20040154623 | Schaeffer et al. | Aug 2004 | A1 |
20040193100 | Van Hooser et al. | Sep 2004 | A1 |
20040193101 | Van Hooser et al. | Sep 2004 | A1 |
20040215142 | Matheis et al. | Oct 2004 | A1 |
20040221853 | Miller | Nov 2004 | A1 |
20040255951 | Grey | Dec 2004 | A1 |
20050004560 | Cox | Jan 2005 | A1 |
20050033267 | Decaria | Feb 2005 | A1 |
20050033268 | Decaria | Feb 2005 | A1 |
20050033269 | Decaria | Feb 2005 | A1 |
20050038381 | McMichael | Feb 2005 | A1 |
20050065468 | Goebel | Mar 2005 | A1 |
20050124932 | Foster et al. | Jun 2005 | A1 |
20050124935 | McMichael | Jun 2005 | A1 |
20050137619 | Schewe et al. | Jun 2005 | A1 |
20050166924 | Thomas et al. | Aug 2005 | A1 |
Number | Date | Country |
---|---|---|
2353007 | Jun 2000 | CA |
19500550 | Jul 1996 | DE |
19855521 | Jun 2000 | DE |
0884061 | Jun 1998 | EP |
1267981 | Apr 2000 | EP |
1005877 | Jun 2000 | EP |
1135184 | Jun 2000 | EP |
2168256 | Jun 1986 | GB |
WO 9522367 | Aug 1995 | WO |
WO 0027461 | May 2000 | WO |
WO 0032262 | Jun 2000 | WO |
WO 0032263 | Jun 2000 | WO |
WO 03045487 | Jun 2003 | WO |
WO 2004067262 | Aug 2004 | WO |
WO 2004101046 | Nov 2004 | WO |
WO 2006023486 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20080142016 A1 | Jun 2008 | US |